Observational Study on Cardiovascular and Kidney Outcomes in CKD Patients with Heart Failure and Preserved Ejection Fraction Using Flozins

What this Trial Is About

This research aims to comprehensively evaluate cardiovascular and kidney outcomes in patients with chronic kidney disease CKD and heart failure with preserved ejection fraction HFpEF. It focuses on how SGLT2 inhibitor therapy affects endothelial function, major adverse cardiovascular events MACE, and mortality. Researchers will use a variety of clinical evaluations, imaging techniques, blood tests, and novel biomarkers to study these effects. The study observes two groups of patients those with CKD and HFpEF receiving SGLT2 inhibitor therapy and those not receiving this therapy. They will be assessed using arterial stiffness measurements by tonometry, echocardiography to examine heart structure and function, blood tests for biomarkers, and metabolomics profiling. These assessments will help understand cardiovascular and renal outcomes over time. Participants will undergo evaluations including flow-mediated dilatation, pulse wave velocity, intima-media thickness measurements, echocardiograms, and blood sampling for biomarker and metabolomics analysis. Researchers will monitor outcomes such as MACE and mortality over 10 to 20 months, as well as kidney function decline. This observational study is designed to gather detailed health information without altering participants treatments, lasting up to nearly three years from the start date.

Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients